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A B S T R A C T
Nanoparticles (NPs) have undergone extensive investigation as drug delivery and targeting vehicles. NP delivery
is often via the parenteral route, reliant on administration using hypodermic needles, which can be associated
with patient compliance issues and safety concerns. In the recent past, the intradermal delivery of NPs, via novel
dissolving microneedle (MN) arrays has garnered interest in the pharmaceutical community. However,
published studies using this combinatorial approach have been limited, in that they have focussed on the use
of in vitro and ex vivo models only. The current study was designed to answer the fundamental question of how
such NPs are distributed in an in vivo murine model, following MN-mediated delivery. Rhodamine B (RhB) was
employed as a model tracer dye to facilitate study of biodistribution. Following MN application, RhB was
detected in the livers, kidneys, spleens and superﬁcial parotid lymph nodes of the mice. Uptake into the
lymphatics was of particular note, as it points towards the potential for utilisation of a minimally-invasive MN
delivery strategy in controlled targeting of active drug substances and vaccines to the lymphatics. The use of
such a delivery system could, following further development, have far-reaching beneﬁts in enhancement of
immunomodulatory and anti-cancer therapies. As a consequence, further investigation of MN/NP combinatorial
delivery strategies is warranted.
1. Introduction
Nanomedicine can be deﬁned as the use of nanoscale or nanos-
tructured materials in medicine, eliciting medicinal eﬀects [1,2]. The
interest in this discipline has grown exponentially over the course of the
last 25 years. One of the main areas of focus of nanomedicine is drug
delivery. Nanoparticles (NPs) have been extensively used as vehicles to
deliver drugs, vaccines, proteins and nucleotides [3]. As demonstrated
in the literature, a wide variety of NP formulations have been fabricated
using compounds such as lipids, polymers, sugars or metals, among
many others [4]. NPs exhibit distinctive, size-dependent physico-
chemical properties and present numerous advantages over conven-
tional drug delivery systems [2,5]. This mode of delivery provides
protection for encapsulated cargo against proteolytic or chemical
degradation and allows sustained drug release over prolonged periods
of time [4]. In addition to these capabilities, NPs can also provide
targeted drug delivery to certain parts of the body when modiﬁed with
particular ligands [6].
The routes of administration for NP formulations are diverse and
include intravenous, pulmonary, oral, nasal and ocular delivery [7].
Oral delivery is often the preferred route, but it presents several
drawbacks, predominantly, drug degradation in the gastrointestinal
tract and lack of NP absorption in the small intestine. In addition to this,
ﬁrst-pass metabolism can potentially destroy a drug before it can reach
the systemic circulation [8,9]. Consequently, the parenteral delivery
route is viewed as a viable alternative to oral delivery. This route allows
direct administration of nanomedicines into the bloodstream, or
directly into a speciﬁc tissue, thus bypassing the aforementioned
limitations associated with the gastrointestinal tract [10]. However,
the parenteral route relies on administration using hypodermic needles,
signiﬁcantly reducing patient compliance, as it is often associated with
pain [11]. Furthermore, this route of administration results in the
generation of medical sharps waste, increasing the risk of disease
transmission by needle re-use or needle-stick injury. This is of particular
concern in countries in the developing world [12].
An alternative to these delivery strategies is via the transdermal
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delivery route. Transdermal delivery systems allow the administration
of medicines in a non-invasive manner, potentially allowing self-
administration. However, the barrier properties of the outermost layer
of the skin, the stratum corneum (SC), limits the number of drugs that
can be administered via this route to those with very speciﬁc physio-
chemical properties, most notably small size [13,14]. Accordingly,
passive permeation of NPs through this layer is extremely limited [4].
One possible means of improving NP administration may be through
the use of microneedles (MNs). MNs are minimally-invasive devices
that allow intradermal and transdermal administration of vaccines and
drug substances by painless penetration of the SC [8,15–18]. MNs can
be self-administered [19,20] and, due to their unique ability to
facilitate administration of drugs and vaccines across the skin, they
have garnered much attention over the past decade [18,19].
The intradermal delivery of NPs viaMNs has undergone some rather
limited investigation over the course of recent years, but the majority of
the studies carried out to date have focused solely on in vitro and ex vivo
experiments. Indeed, few studies have investigated MN/NP combina-
torial delivery systems in vivo [2]. Accordingly, in the present explora-
tory study, we probed, for the ﬁrst time, the biodistribution of a model
water soluble compound following MN delivery. Both NP-encapsulated
rhodamine B (RhB) and free-RhB were utilised in this work, so as to
elucidate any diﬀerences. Speciﬁcally, the inﬂuences of using MN
arrays containing RhB-loaded NPs (RhB/NP) in the needles and not
the baseplate and MN arrays loaded with free-RhB were evaluated in an
in vivo murine model.
2. Material and methods
2.1. Materials
Rhodamine B chloride, acetonitrile, methanol, poly(vinylpyrroli-
done) (PVP) K90 and hydrochloric acid (HCl) were purchased from
Sigma-Aldrich (Gillingham, Dorset, UK). Poly(lactic-co-glycolic acid)
(PLGA) RG504H, was obtained from Boehringer Ingelheim GmbH
(Ingelheim, Germany). Sodium hydroxide (NaOH) was obtained from
VWR International (Lutterworth, Leicestershire, UK). PVP K29/30 was
obtained from Ashland Inc. (Kidderminster, UK).
2.2. Fabrication of biodegradable PLGA nanoparticles
The NPs were fabricated by nanoprecipitation, also termed solvent
displacement, as documented previously [21,22]. The method was
adapted and modiﬁed from a previous publication [23]. In brief, for
each batch of NPs, 10 mg PLGA (RG504H) was dissolved in 9.7 ml of
acetone containing 0.3 ml of 0.1 mg ml−1 RhB. The PLGA/acetone
mixture was then added to 10 ml of water and stirred at 800 rpm (rpm)
until the acetone evaporated. Once the NPs were formed, the suspen-
sion was dialysed for two days using dialysis membrane with molecular
weight cut-oﬀ of 14 kDa, to facilitate removal of any unbound RhB. PVP
(58 kDa) was then added to the nanosuspension as cryoprotectant in a
ratio of PVP to NPs, 2:1. The cryoprotectant was mixed into the
suspension by adding the desired quantity of polymer and allowing
the suspension to mix for at least 30 min to ensure the cryoprotectant
had completely dissolved prior to freeze-drying. PLGA NPs were then
dried using the freeze-drying cycle outlined in Table 1. The resulting
NPs were characterised using a Zetasizer Nano ZS (Malvern Instruments
Malvern, Worcestershire, UK).
2.3. Determination of the amount of RhB encapsulated in the NPs
To determine the amount of RhB encapsulated in PLGA NPs, three
samples of known mass were taken from freeze dried powder samples.
These samples were re-suspended in a known volume of 1 M NaOH and
left overnight in order to dissolve the PLGA NPs. Following 24 h, the
solutions were neutralised with 1 M HCl. The neutralised solutions were
diluted two-fold with high performance liquid chromatography (HPLC)
grade water. HPLC analysis was carried out on an Agilent Technologies
1200 Series system, with an auto sampler, binary pump, degasser and a
ﬂuorescence detector (Excitation: 546 nm; Emission: 570 nm). A Waters
Symmetry 300™ C4 column thermostatically controlled at 25 °C was
utilised. The mobile phase consisted of a mix of HPLC grade water,
pH 7:organic mixture (80% methanol; 20% acetonitrile), in the ratio
45:55 (v/v). The injection volume was 20 μl, while the ﬂow rate was
1 ml min−1.
2.4. Fabrication of dissolving MNs
The MN were fabricated by primary casting of a NP-containing
formulation into the needles of the MN arrays only, with a very shallow,
cargo-less baseplate behind the needles. The moulds employed in the
study consisted of a 19 × 19 array with needle heights of 600 μm,
width at base of 300 μm and interspacing at base of 50 μm in a mould
area of 0.5 cm2. The MN fabrication methodology was modiﬁed from
previously published studies [24,25]. Initially, a silicone frame was
designed and aﬃxed into pre-manufactured silicone MN moulds [24]
using a small amount of PVP-gel on the underside of the frames. These
frames were then dried into the moulds at room temperature for
45 min. The framed-moulds were then used to cast NP-containing
formulation into the needles only. To achieve this, a quantity of
primary casting gel (30% (w/w) 58 kDa PVP aqueous solution, with
an equal mass of the freeze dried NPs), suﬃcient to cover the array, was
added into the framed-mould and spread within the framed area using a
spatula. The moulds were then centrifuged for 10 min at 3500 rpm.
After centrifugation, the frames were removed from the moulds and the
arrays were dried at room temperature for 1.5 h. Post-drying, a pre-
formed baseplate, consisting of 15% (w/w) 360 kDa PVP, was placed
behind the needles cast into the moulds using 10 μl of 50% (w/w)
360 kDa PVP as an adhesive. The moulds were then centrifuged at
5000 rpm for 90 min and the arrays were dried overnight at room
temperature. Control MN arrays containing equivalent amounts of free-
RhB were also prepared. A schematic representation of this methodol-
ogy is presented in Fig. 1A.
2.5. Application of MN arrays
The transdermal delivery of RhB-loaded NPs and free-RhB using
dissolving MN arrays was evaluated using hairless mice (strain SKH1-
Hrhr). All animal experiments throughout this study were conducted
according to the policy of the Federation of European Laboratory
Animal Science Associations and the European Convention for the
protection of vertebrate animals used for experimental and other
scientiﬁc purposes, with implementation of the principles of the 3R's
(replacement, reduction, reﬁnement). Ethical permission for the experi-
ments was obtained from the Queen's University Belfast, Biological
Services Unit (BSU) and the work was carried out under Project Licence
2794, as granted by the UK Home Oﬃce. Mice employed in the study
Table 1
The freeze-drying cycle for NP drying.
Step Temperature (°C) Pressure (torr) Time (min) Type of step
1 5 760 10 Hold
2 −40 760 60 Ramp
3 −35 190 180 Hold
4 −30 190 60 Ramp
5 −30 190 180 Hold
6 −25 190 60 Ramp
7 −25 190 180 Hold
8 25 190 120 Ramp
9 25 190 360 Hold
10 25 50 600 Hold
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were aged between 14 and 18 weeks and both males and females were
used. Mice were anaesthetised using gaseous anaesthesia (2–4%
isoﬂurane in oxygen) and MNs were inserted, with pressure applied
for 5 min, to the dorsal surface of the right ear and kept in place for 24 h
with 3M™Micropore™medical tape (3M™, St. Paul, MN, USA) cut into a
T-shape. The application process is documented in Fig. 1B. All MN
arrays were removed after 24 h.
2.6. In vivo visualisation of NP-derived RhB and free-RhB using IVISR
imaging tool
In order to visualise the uptake of RhB-loaded NPs or free-RhB over
time, an in vivo imaging system (IVISR) was utilised (Xenogen IVISR
Imaging System 200 Series, Caliper LifeSciences, Hopkinton, MA). In
total, twelve mice were imaged at four predetermined time intervals,
namely: 24, 48, 120 and 168 h post-application. After seven days of
imaging, all mice were euthanised and superﬁcial parotid lymph nodes,
spleens, livers, kidneys, and right ears were all excised and imaged.
Speciﬁcally, the mice were split into four groups: (i) three males
were treated with RhB-loaded NP incorporated into MN (RhB/NP MNs);
(ii) three males were treated with free-RhB incorporated into MN (free-
RhB MNs); (iii) three females treated with RhB/NP MNs and (iv) three
females treated with free-RhB MNs. This identiﬁcation terminology was
subsequently used throughout the study.
2.7. Quantiﬁcation of RhB localised in mouse organs
The ﬂuorescence intensity of the NP-delivered or free-RhB was also
measured using IVISR. Utilising 21 male and 21 female mice, three
cohorts, consisting of seven mice each, were assembled, namely: 24, 48
and 120 h. In all instances, six mice had MN applied to the right ear and
one mouse, an untreated control, was also included in the cohort. Half
of the males and half of the females in each cohort had RhB/NP MNs
applied and the other half had free-RhB MNs applied. At the pre-
determined experimental end points, the mice were euthanised and the
superﬁcial parotid lymph nodes, spleens, livers, kidneys and right ears
were removed, weighed and imaged. Following removal of MN from
the ears, the area was cleaned with tissue paper soaked in 70% (v/v)
alcohol so as to prevent superﬁcial tracer dye causing overestimation in
ﬂuorescence signals. For biodistribution studies, the ﬂuorescence read-
ing was corrected by subtracting the mean readings from the control
tissue and normalised by dividing with the tissue mass, as outlined by
Merkel et al. [26].
3. Results
The mean particle size of RhB-loaded NPs in a representative batch
was determined to be 69.3 ± 4.6 nm, with a polydispersity index of
0.27 ± 0.03, n = 6.
Dissolving MN arrays were then fabricated in such a way as to
maximize the amount of RhB loaded into each array. Upon preparation
of the RhB/NP or free-RhB casting gels, the mean concentrations
(ng mg−1) and amounts (μg) of RhB in the representative gels and in
the subsequent MN arrays produced were determined, with data
presented in Table 2.
Fig 2A and B shows representative images of the dissolving MN
arrays containing RhB/NPs which were localised into the needles
themselves.
The MN arrays were successfully inserted into the ears of the mice
and held in place for 24 h. They were then removed and the remnants of
the MNs were imaged using a light microscope (VHX-700F digital
microscope, Keyence, Milton Keynes, UK). As illustrated in the repre-
sentative images presented in Fig. 2C and D, the vast majority of
needles on the arrays dissolved following application to mouse ears for
24 h.
The ﬂuorescence intensity of the NP-delivered and free-RhB deliv-
ered into the ears using MNs were visualised using the IVISR system.
IVISR images of three male and three female control mice from the
treatment cohorts are presented in Fig. 2E. As these mice received no
MN treatment, there is consequently no evidence of RhB delivery to the
ears of these mice. To study the varying drainage of RhB/NPs and free-
RhB from the ears of treated mice, images of a single representative
male or female mouse from each of the two treatment cohorts, taken at
pre-determined time intervals (24, 48, 120 or 168 h), are presented in
Fig. 2F (RhB/NP cohort) and 2G (free-RhB cohort). Comparison of the
Fig. 1. Schematic representation of the fabrication process of the dissolving MN arrays (A). Digital photographs of the MN application process to the dorsal surface of mouse ears in vivo
(B).
Table 2
Concentrations (ng mg−1) and amounts (μg) RhB in the casting gels and MN arrays,
respectively. The values are given as the mean ± standard error, n = 6.




RhB/NP MNs NP encapsulated RhB 226 ± 13 7.8 ± 0.3
Free-RhB MNs Free-RhB 208 11.7 ± 0.6
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images presented in the two ﬁgure panels makes it obvious that more
RhB was delivered into the ears of the mice when MN arrays containing
free tracer dye (free-RhB) were used rather than RhB/NP MN arrays. In
both delivery approaches, the signal decreased over time. This suggests
that, in both instances, the free-RhB or RhB/NPs migrated from the ear
and did not accumulate there. After seven days, the signal returned to
baseline levels in all mice tested.
The IVISR system captures images from above, imaging the
transverse plane of the subject. Therefore, it is not possible to obtain
an accurate ﬂuorescent intensity reading using this image plane. To
record more accurate readings, mice were culled at pre-determined
time points and the ears to which the MN arrays were applied were
removed and imaged along the coronal plane. The number of photons
recorded was divided by the mass of the excised ear, to produce a
“concentration” of photons per mass of tissue, as previously outlined by
others [26]. The concentrations of photons per mass of tissue for the
two treatment cohorts (free-RhB and RhB/NP) are presented in Fig. 3A
and B. In the cases of both male and female mice, the greatest
concentrations of free-RhB and NP derived RhB were present in excised
ears 24 h post-MN application. It is evident that after 120 h, the free-
RhB and NP-derived RhB have migrated away from the ear as the
concentrations have markedly decreased. Comparing between the two
genders, it appears that the uptake in the females is faster than the
males for both free-RhB and NP-derived RhB, as the concentration
diﬀerence between 24 h and 48 h post-application is greater, showing a
steeper change in the curve. Other properties of the curves are recorded
in Table 3.
In order to determine which organs the RhB was delivered to, mice
were culled 48 h post-MN application and speciﬁc organs were excised.
These were placed on a dark sheet and imaged using the IVISR with
sample images presented in Fig. 4. The ﬂuorescence measured was then
used to determine the biodistribution of RhB in the mice.
The free-RhB and RhB/NPs delivered into the ears may be taken up
either by the blood or lymph capillaries. If taken up by the lymph
capillaries, it would drain to the nearest lymph node, the superﬁcial
parotid lymph node. RhB/NPs may also be taken up by antigen-
presenting cells in the viable skin layers, which then migrate to the
draining lymph node. This is less likely to happen for free RhB. To
assess the degree of lymphatic uptake of the free-RhB or NP-derived
RhB, the superﬁcial parotid lymph nodes were extracted (Fig. 4). As the
lymphatic circulatory system is one uniﬁed system, the concentration in
the whole lymphatic system should reach a uniform concentration level
[27]. As a result, the free-RhB and NP-derived RhB should be detectable
in both the left and right (same side as MN application) superﬁcial
parotid lymph nodes. Consequently, the concentration of RhB in the left
superﬁcial parotid lymph node can be used to determine when the
levels of free-RhB and NP-derived RhB in the lymphatic circulatory
system have reached a steady state. The concentration of free-RhB and
Fig. 2. Digital images of the dissolving RhB/NP MN arrays before insertion into mouse ears (A and B). Micrographs of MN arrays loaded with RhB/NPs (C) and free-RhB (D), post-24 h
application to mouse ears. IVISR images of three male and three female mice from the control treatment cohorts (i.e. no MN applied to the ears) (E). Fluorescence detected at diﬀerent
time points (24, 48, 120 or 168 h), post-MN application in test mice from the RhB/NP MN cohort: male (upper panel) and female (lower panel) mice captured using the IVISR system (F).
Fluorescence detected at diﬀerent time points (24, 48, 120 or 168 h), post-MN application in test mice from the free-RhB MN cohort: male (upper panel) and female (lower panel) mice
captured using the IVISR system (G). In all instances, the colour indicates how many photons were detected.
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NP-derived RhB in the superﬁcial parotid lymph nodes are graphically
presented, as a function of time, in Fig. 5A. The concentrations of free-
RhB and NP-derived RhB in spleens, livers and kidneys are then
presented in Fig. 5B, C and D, respectively.
As depicted in Fig. 5A, the time taken for the NP-derived RhB to
reach detectable levels in the lymph nodes exceeded 24 h. Also, the
concentration in the lymphatic circulatory system had not reached a
steady state, even 48 h post-application. The concentration of NP-
derived RhB in the right lymph nodes was consistently higher than that
detected in the left lymph nodes, with the highest concentration of NP-
derived RhB in the lymph nodes recorded 120 h post-application. It was
not possible to determine whether this was the maximal concentration,
however, as it is possible a maximal concentration had been reached
between the 48 and 120 h sampling times. Seven days (168 h) post-
application, the ﬂuorescence readings returned almost to basal levels.
Male mice appeared to clear free-RhB faster than the NP-derived RhB,
while female mice exhibited very similar concentrations of free-RhB
and NP-derived RhB in the lymph nodes up to 168 h post-application.
The NP-derived RhB concentrations in the lymph nodes one week post-
MN application were approximately the same in both male and female
mice. Pharmacokinetic properties were calculated from the curves
generated in Fig. 5A and are summarised in Table 4.
Another organ of the lymphatic system is the spleen. The concen-
trations of free-RhB and NP-derived RhB in the spleens of treated mice,
as a function of time, are presented in Fig. 5B and the summary of the
properties determined from this graph are displayed in Table 5.
Irrespective of delivery vehicle, the concentrations of RhB in the
spleens was approximately an order of magnitude lower than that
recorded in the superﬁcial parotid lymph nodes. For those mice treated
with free-RhB loaded MN arrays, RhB was detected in the spleen 24 h
post-application, while those mice treated with RhB/NP loaded MN
arrays did not have any detectable concentrations of the molecule until
48 h post-application.
The third organ investigated was the liver. With its rich blood
supply, and the fact that most of the detoxiﬁcation in the body occurs in
the liver, the concentration of free-RhB and NP-derived RhB in the liver
can be used to proﬁle systemic exposure to this molecule. The
concentration of RhB measured in the livers of treated mice, as a
function of time, is presented in Fig. 5C and the summary of the
properties calculated from this graph are displayed in Table 6. As
depicted in Fig. 5C, free-RhB and NP-derived RhB have diﬀerent
concentration proﬁles in this organ. The free-RhB proﬁle is indicative
of the normal pharmacokinetics of a drug injected subcutaneously;
ﬁrstly, a rapid absorption phase with a maximal concentration
recorded, followed by a slower elimination phase. This is compared
to the proﬁle for the NP-derived RhB, where the concentration
increased to a maximal level and then remained constant up to ﬁve
days' post-application, when the concentration then decreased. In the
case of NP-derived RhB, there were no detectable levels of RhB in the
livers until 48 h post-application. The concentration of the molecule
remained relatively constant after the 48 h and it was slowly eliminated
thereafter. Comparing the area under the curve (AUC) and the maximal
concentration of RhB, Cmax, in order to compare between the two MN
application methods, it can be seen that both values are lower in the
case of the RhB/NP MNs. However, direct comparison cannot be made,
as the two types of MNs presented slightly diﬀerent RhB loadings
(Table 2).
The kidney is responsible for the ﬁltering and excretion of unwanted
materials from the body. Thus, as RhB is being excreted, it passes
through the kidneys. As a result, the photons measured in the kidneys
are indicative of RhB which is possibly being prepared for excretion.
The concentration proﬁle of RhB in the kidneys is graphically presented
in Fig. 5D. The concentration proﬁles of males and females were
markedly diﬀerent. In females, detectable RhB was only recorded at
24 h from free-RhB-loaded MN. It is not clear why no other detectable
RhB was recorded. Males treated with free-RhB MNs displayed faster
accumulation of RhB and also a larger Cmax, as can be seen in Fig. 5D
and presented in Table 7. The maximal concentration of RhB measured
for the free-RhB cohort was at 48 h post-application, while the RhB/NP
cohort displayed a maximal concentration in the kidneys at 120 h post-
application.
4. Discussion
Here we have shown, for the ﬁrst time, that NPs delivered into the
viable skin layers using MNs can be absorbed and distributed through-
out the body.
When the MNs were applied to the ears of mice and held in situ for
24 h, the majority of the needles on the arrays dissolved. Following
visual inspection of the MNs, RhB delivery into the mice was conﬁrmed
by carrying out in vivo and ex vivo imaging using an IVISR image
system. NPs delivered using MNs appeared in the lymphatic system at a
slightly slower rate than free RhB and free RhB appeared in the kidneys
more quickly than the NP-bound dye. Biodistribution in other organs
(spleen, liver) indicated higher RhB-associated ﬂuorescence in the
groups treated with free-RhB MNs. Biodistribution in female mice
should distinct diﬀerences with that in males for both free and NP-
bound dye. The reasons for this were not apparent, since the mice had
Fig. 3. The normalised concentrations of photons per mass of tissue in the excised ears of male (A) and female (B) mice, plotted as a function of time (RhB = free-RhB; NP = RhB/NP).
The values presented are the means ± standard error, n = 3.
Table 3
Data obtained from the curves for free-RhB and RhB/NP in mice ears. AUC was calculated
from the mean curve. Values are given as means ± standard error, n = 3.
Sex/formulation tmax (h) Cmax/107 (photons/mg) AUC
Male/RhB/NP 24 4.1 ± 1.4 3.31 × 109
Male/free-RhB 24 14.8 ± 5.9 9.76 × 109
Female/RhB/NP 24 7.3 ± 2.2 3.53 × 109
Female/free-RhB 24 23.2 ± 9.7 7.89 × 107
J. Kennedy et al. Journal of Controlled Release xxx (xxxx) xxx–xxx
5
similar weights and levels of physical activity, regardless of gender or
formulation applied, including untreated controls.
In general, small drug molecules (< 1 kDa) are thought to be
preferentially absorbed by the blood capillaries, due to their largely
unrestricted permeability across the vascular endothelium, together
with the high rate of ﬁltration and reabsorption of ﬂuid across the
vascular capillaries (in the range of 20–40 l/day, in comparison to
approximately 2–4 l/day of ﬂuid drained by the lymph). A small
molecule such as RhB should, therefore, predominantly be taken up
by the blood capillaries of the dermal microcirculation, even though it
has appreciable water solubility. In contrast, NPs which are too large
(limits < 10 nm in size, or approximately 16–20 kDa for proteins) to
be taken up by the blood capillaries should only be taken up by the
lymphatics (10–100 nm for particles and 20–30 kDa for proteins) [28].
That RhB was found in the left ear lymph node, as well as that on the
right and in distant organs following MN delivery of RhB NPs conﬁrms
that these particles were absorbed into the lymphatic system and then
entered the systemic circulation. The removal of unbound RhB from the
particles during formulation strongly suggests that the biodistribution
observed is due to the particles themselves and not to released RhB.
Following initial delivery of RhB into the ears of the mice via either
free-RhB MN or RhB/NP MN, the ﬂuorescence signal at the delivery site
became weaker over time, indicating that the free-RhB and NP-bound
RhB were both migrating away from the ear. The elucidation of the
exact mechanism by which this occurs is worthy of further investiga-
tion. The stronger ﬂuorescence signal elicited following application of
free-RhB MN suggests that a greater amount of RhB was delivered into
those ears than when RhB/NP MN were employed. This was despite the
fact that the MN arrays essentially had the same amount of RhB loaded
into the needles.
A ﬂuorescence signal from RhB/NPs was still detected at the
injection site 48 h post-application. This supports previously-reported
ﬁndings, which have documented that draining to the lymphatics is
slower in certain regions of the body and that it can take up to 48 h for
NPs to be detected in the draining lymph nodes [29]. The lymphatic
circulatory system is a unidirectional circulatory system without a heart
Fig. 4. Sample IVISR images of parotid lymph nodes, spleens, livers and kidneys removed from control (no MN treatment) male and female mice (A), RhB/NP (NP) treated male and
female mice (B) and free-RhB (RhB) treated male and female mice (C). All images are from mice which were culled 48 h post-MN treatment.
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to pump the lymph around. Instead, the ﬂuid is moved around through
muscle movements. This explains why lymphatic uptake is much faster
for injections in the limbs than in the ears, for example. Another study,
which injected NPs subcutaneously into the footpad of rats, recovered
15% of the injected NP in the draining lymph node after 24 h, while
65% remained in the footpad [23]. This can be compared to the results
in the present study, where no detectable levels of RhB in the draining
lymph node were achieved 24 h post-application of RhB/NP MNs,
proving that the draining from the ear and subsequent lymphatic
uptake of the RhB/NP is relatively slow. Indeed, it has previously been
shown that free-RhB injected subcutaneously completely migrated
away from the injection site within 24 h, compared to RhB attached
to polymeric surfactants, which was still present at the injection site
72 h post-injection [30]. In the same study, free-RhB was detected in
the urine of the mice one to four hours after the injection. The free RhB,
therefore, entered the systemic circulation quickly and was excreted by
the mice. In the present study, it is clear that free-RhB enters the
lymphatic system quite quickly. It is likely that at least some of the
delivered dose is passively drained into the draining lymphatic adjacent
to the application site. Some free-RhB may also enter the lymphatic
system from the plasma, having previously been absorbed by the
dermal microcirculation. This is in contrast to the NP-bound dye, which
Fig. 5. The normalised concentrations of photons, indicative of free-RhB (RhB) or NP-derived RhB (NP) delivery per mass of tissue in the superﬁcial parotid lymph nodes (A), spleens (B),
livers (C) and kidneys (D) of male or female mice, plotted as a function of time. The values shown are the means ± standard error, n = 6.
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is likely to predominantly rely on slow drainage of interstitial ﬂuid to
carry it to the lymphatics for uptake. However, work previously carried
out in our Group showed that ﬂuorescently-labelled antigen-decorated
NPs were taken up by professional antigen-presenting cells in the viable
skin of mice in vivo and traﬃcked to the draining lymph nodes [31].
This process took approximately 48 h. If the PLGA used to make the NPs
in the present study contained any lipopolysaccharide, it is possible that
some of the NPs could have been carried slowly to the draining lymph
node following cellular uptake,
The photon concentration proﬁles in the organs studied (spleen,
liver, kidneys) all showed a delay in appearance for the NP-bound RhB,
relative to the free dye. The peak ﬂuorescence was also lower for the
NP-bound dye. With the exception of the kidneys of female rats, where
it didn't appear at all, the ﬂuorescence due to the NP-bound RhB took
longer to clear that due to the free dye. While the data overall may be
inﬂuenced to some extent by the slightly lower RhB loading in the NP-
laden MNs (Table 2) and the possibility of somewhat quenched
ﬂuorescence in the NPs, delayed appearance in and clearance from
organs is most likely to be due to the distinctly diﬀerence biodistribu-
tion of the NP-bound dye. This is likely to be at least partly because it
took longer for the RhB/NPs to enter the systemic circulation relative to
free dye. Since the NPs are too large to be taken up by the blood
capillaries, they must have entered the lymph vessels in the skin and
migrated though the lymphatic system before they could enter the
systemic circulation. Indeed, while the spleen forms an integral part of
the lymphatic system, it only has eﬀerent lymph vessels. This means it
is only supplied by the cardiovascular system and, as a result, the NP-
associated RhB ﬂuorescence detected in the spleen here must have
come from the general circulation.
It is likely that the RhB/NPs will diﬀuse more slowly through the
dermal tissue than the free RhB molecules, which consequently means it
will take longer for the RhB/NPs to migrate away from the application
site than the free-RhB molecules. This phenomenon has been reported
in a previous study, which compared the uptake of a free tracer with
that of NPs following subcutaneous injection [32]. In Fig. 3, it can be
seen that the photon concentration of the free-RhB is higher at the
application site compared to that at the application site of the RhB/NPs
but, in line with other published studies, the photon concentration
decrease over time is faster, indicating that the draining of free-RhB is
faster than that of RhB/NPs.
Biodistribution in the regional lymph nodes, liver, spleens, and
kidneys is known to be dependent upon the injection/application site
[32]. Since lymph is moving towards the base of the neck, where it
ﬂows into the subclavian veins and enters the cardiovascular system, it
is expected that injection/application sites closer to the neck will result
in a shorter distribution time for the NPs, with more of the NPs entering
general circulation in the cardiovascular system. This is what was
observed in the present study, complementary to that reported by
others previously which found that smaller particles which had a higher
lymphatic uptake also travelled faster through the lymphatic circula-
tory system and entered general circulation, resulting in a higher blood
concentration and liver uptake [23,33]. This is in contrast to the results
generated when particulates were injected subcutaneously into mice
paws where twice the amount of NPs were recovered in the lymph
nodes, compared to the liver and blood, 24 h post-injection [34]. Using
these previously documented studies and the results presented here, it
can be concluded that the NPs are being taken up by the lymphatic
circulatory system, but are also travelling through the lymphatics and
entering the systemic circulation. Importantly, the experimental ap-
proach undertaken in the present study is likely to have inﬂuenced the
kinetics, and possibly also the extent, of the observed biodistribution,
since the MN application site used here is relatively close to the
subclavian veins where the lymph drains.
It is clear that, in the present study, the MN-delivered NPs entered
the lymphatic system, but did not remain there. However, there are
numerous medical applications where lymphatic targeting and reten-
tion would be advantageous. These include not only vaccination and
immunomodulation, but also enhanced treatment of tumours of the
lymphatic system and management of metastases of solid tumours,
which typically occurs through the lymphatics. If vaccines and ther-
apeutic agents could be dosed mostly to their site of action in the
lymphatics, therapeutic eﬃcacy would most likely be increased and
side-eﬀects reduced. The retention of particulates, including NPs, in the
lymph is mainly due to phagocytosis by macrophages [35]. As the use
of smaller particles results in greater lymphatic uptake, but employing
larger particles leads to more eﬃcient lymphatic retention, a range of
pharmaceutical interventions have been developed in a bid to increase
lymphatic retention of drug molecules, including surface modiﬁcations,
such as addition of branched polymers to NP surfaces [23,34,36].
5. Conclusion
In this exploratory study we showed, for the ﬁrst time, that NPs
delivered intradermally using dissolving MNs entered the lymphatic
system. MN delivery, therefore, shows clear potential as a minimally-
Table 4
Properties of concentration versus time curves for free-RhB and RhB/NP in either left (L)
or right (R) superﬁcial parotid lymph nodes. AUC was calculated from the mean curve.
Values given are means ± standard error, n = 3.
Sex/formulation L/R tmax (h) Cmax/107 (photons/mg) AUC/109
Male/RhB/NP L 120 3.9 ± 2.2 3.01
Male/RhB/NP R 120 3.8 ± 0.4 3.26
Male/free-RhB L 120 4.5 ± 1.7 4.08
Male/free-RhB R 120 4.1 ± 0.9 4.00
Female/RhB/NP L 120 2.1 ± 0.7 2.08
Female/RhB/NP R 120 4.1 ± 0.5 3.82
Female/free-RhB L 48 3.1 ± 1.3 2.82
Female/free-RhB R 120 2.3 ± 0.2 2.65
Table 5
Properties of the concentration versus time curves for free-RhB and RhB/NP in mouse
spleens. AUC was calculated from the curve of concentration vs. time. Values given are
mean ± standard error, n = 3.
Sex/formulation tmax (h) Cmax/106 (photons/mg) AUC/108
Male/RhB/NP 120 2.8 ± 0.7 2.13
Male/free-RhB 120 3.5 ± 1.1 3.93
Female/RhB/NP 120 2.2 ± 1.0 2.06
Female/free-RhB 120 1.2 ± 0.4 1.46
Table 6
Properties of the concentration versus time curves for free-RhB and RhB/NP in mouse
livers. AUC was calculated from the curve of concentration vs. time. Values given are
mean ± standard error, n = 3.
Sex/formulation tmax (h) Cmax/105 (photons/mg) AUC/107
Male/RhB/NP 48 2.4 ± 0.9 2.13
Male/free-RhB 24 4.1 ± 0.5 3.93
Female/RhB/NP 120 2.8 ± 0.5 2.06
Female/free-RhB 24 4.4 ± 1.6 1.46
Table 7
Properties of the concentration versus time curves for free-RhB and RhB/NP in mouse
kidneys. AUC was calculated from the curve of concentration vs. time. Values given are
mean ± standard error, n = 3.
Sex/formulation tmax (h) Cmax/105 (photons/mg) AUC/107
Male/RhB/NP 120 4.2 ± 2.5 4.05
Male/free-RhB 48 6.9 ± 0.9 7.00
Female/RhB/NP – – –
Female/free-RhB 24 0.8 ± 1.7 0.19
J. Kennedy et al. Journal of Controlled Release xxx (xxxx) xxx–xxx
8
invasive alternative to subcutaneous delivery of nanoparticulate car-
riers intended for vaccination purposes or management of diseases of
the lymphatic system. However, we were not able to control retention
in the lymphatics. This is unsurprising, given that the particles
employed were not speciﬁcally modiﬁed to prevent subsequent biodis-
tribution via the systemic circulation. Since such work has never before
been done, further understanding must now be developed. For example,
we employed a single particle type with ﬁxed size and charge here.
Modulation of these parameters, along with alteration of the polymer
matrix to control lipophilicity may well have profound eﬀects on
lymphatic uptake and retention. Similarly, MN application site is also
likely to inﬂuence uptake and retention kinetics. Now that we have
proved that MN-delivered NPs can enter the lymphatics, we have
embarked upon a comprehensive programme of work to enhance
retention and maximize dosing eﬃciency.
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